Market revenue in 2023 | USD 115.8 million |
Market revenue in 2030 | USD 162.2 million |
Growth rate | 4.9% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Abbott Laboratories, Thermo Fisher Scientific Inc, Roche Holding AG ADR, Qiagen NV, Siemens Healthineers AG ADR, Becton Dickinson & Co, Illumina Inc, Epigenomics AG, Koninklijke Philips NV, FUJIFILM Holdings Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liver cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 58.46% in 2023. Horizon Databook has segmented the Spain liver cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Spain is expected to witness lucrative growth in the near future owing to increase in prevalence of hepatitis B & C and liver cirrhosis. It is considered to have the largest number of migrants in Europe. A research study was conducted by Enfermedades Infecciosas y Microbiologic Clinical in April 2019, which aimed at estimating the prevalence of hepatitis C in the migrant population. The study concluded that hepatitis C is mostly observed in the migrant population.
Thus, growing prevalence of the disease is expected to impel market growth, as patients diagnosed with hepatitis C are at higher risk of developing liver cancer. Moreover, prevalence of liver cirrhosis is growing in the country.
Cirrhosis is considered as the last stage in a liver disease. This increase is mainly observed due to rise in incidence of hepatitis C in the ageing population and non-alcoholic fatty liver disease. Hence, due to the aforementioned factors, the market is estimated to grow at a rapid pace.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain liver cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Spain liver cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account